ProPhet
AI-driven Drug Discovery
StartupProPhet is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2024. AI-driven Drug Discovery. The company has raised a total of $1M across 1 funding round, currently at the Pre-Seed stage. ProPhet was founded by Tom Shani, Avital Sharir-Ivry, Amitai Mordechai. Key investors include Merck, AION Labs, AstraZeneca, among 5 total investors. The company has 1-10 employees. Core technologies: Biologicals, Molecules, Artificial Intelligence, Deep Learning, Generative AI, Machine Learning.
With $1M in total funding, ProPhet is a Pre-Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D.
- StagePre-Seed
- ProductR&D
- ModelB2B
- Employees1-10
- HQRehovot
- DistrictCenter District
- Last Round$1M
- Merck
- AION Labs
- AstraZeneca
5 investors total
Tom ShaniCo-founder & CEO
Avital Sharir-IvryCo-founder & CSO
Amitai MordechaiCo-founder & CTO
2 articles covered by sources including www.mako.co.il,
www.prnewswire.com.
What does ProPhet do?
ProPhet is an AI-driven company transforming small molecule drug discovery, with a focus on proteins that are hard to target using competitive methods. The company develops advanced technology to identify potential therapeutics for these challenging targets, addressing a critical need in the pharmaceutical industry. Its innovative approach leverages artificial intelligence and machine learning to speed up and enhance the early stages of drug discovery. By predicting protein dynamics and how they interact with drug candidates, ProPhet can rapidly identify promising molecules. This allows to tackle proteins with limited structural information, opening new possibilities for treating diseases previously considered “undruggable.” ProPhet stands out by combining speed, precision, and scientific rigor. Its AI platform evaluates vast libraries of small molecules, offering faster, more efficient, and cost-effective solutions compared to both traditional and other AI-based methods. By doing so, it helps pharmaceutical companies and researchers explore a broader range of treatments with more accuracy, backed by scientifically interpretable results. Its vision is to revolutionize drug discovery, making it faster and more accessible. ProPhet aims to deliver better solutions to help meet unmet medical needs and improve patient outcomes.
How much funding has ProPhet raised?
ProPhet has raised $1M in total funding across 1 rounds. The company is currently at the Pre-Seed stage. Key investors include Merck, AION Labs, AstraZeneca.
Who founded ProPhet?
ProPhet was founded in 2024 by Tom Shani (Co-founder & CEO), Avital Sharir-Ivry (Co-founder & CSO), Amitai Mordechai (Co-founder & CTO).
What sector is ProPhet in?
ProPhet operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules, Artificial Intelligence, Deep Learning, Generative AI, Machine Learning. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology.
Where is ProPhet located?
ProPhet is based in 4 Oppenheimer Building B 17th Floor, Rehovot, 7670104, Israel, Center District.